Environment-mediated drug resistance: a major contributor to minimal residual disease.
about
β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastomaStem cell technology in breast cancer: current status and potential applicationsThe Role of Chemokines in Promoting Colorectal Cancer Invasion/MetastasisRole of the tumor microenvironment in mature B-cell lymphoid malignanciesBioengineering Models for Breast Cancer ResearchCancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor GrowthTherapeutic strategies targeting cancer stem cellsMetabolic reprogramming: the emerging concept and associated therapeutic strategiesRole of mesenchymal cells in the natural history of ovarian cancer: a reviewMicro-RNAs, New performers in multiple myeloma bone marrow microenvironmentPushing tumor cells towards a malignant phenotype: stimuli from the microenvironment, intercellular communications and alternative roadsChemotherapy-enhanced inflammation may lead to the failure of therapy and metastasisDesmoplasia and chemoresistance in pancreatic cancerNuclear export of proteins and drug resistance in cancerTumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectivesSpatial and functional heterogeneities shape collective behavior of tumor-immune networksThe tumor microenvironment shapes hallmarks of mature B-cell malignancies.Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.On metabolic reprogramming and tumor biology: A comprehensive survey of metabolism in breast cancerCarcinoma-associated fibroblasts: orchestrating the composition of malignancyControlled breast cancer microarrays for the deconvolution of cellular multilayering and density effects upon drug responsesApplication of concave microwells to pancreatic tumor spheroids enabling anticancer drug evaluation in a clinically relevant drug resistance modelDevelopment of an acellular tumor extracellular matrix as a three-dimensional scaffold for tumor engineeringCanonical Wnt pathway inhibitor ICG-001 induces cytotoxicity of multiple myeloma cells in Wnt-independent mannerSpatial heterogeneity in drug concentrations can facilitate the emergence of resistance to cancer therapyKinase Inhibition Leads to Hormesis in a Dual Phosphorylation-Dephosphorylation CycleThe causes and consequences of genetic heterogeneity in cancer evolutionIdelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemiaTumor microenvironment complexity: emerging roles in cancer therapy.β₁Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapyA phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.Breast tumour stroma is a prognostic indicator and target for therapy.TGF-β-independent CTGF induction regulates cell adhesion mediated drug resistance by increasing collagen I in HCCGrowth of tyrosine kinase inhibitor-resistant Philadelphia-positive acute lymphoblastic leukemia: Role of bone marrow stromal cellsMiniaturized pre-clinical cancer models as research and diagnostic tools.Expression profile and specific network features of the apoptotic machinery explain relapse of acute myeloid leukemia after chemotherapy.Tumor associated macrophages protect colon cancer cells from TRAIL-induced apoptosis through IL-1beta-dependent stabilization of Snail in tumor cells.Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myelomaMicroenvironmental regulation of therapeutic response in cancerMesenchymal stem cells contribute to the chemoresistance of hepatocellular carcinoma cells in inflammatory environment by inducing autophagy.
P2860
Q24564890-F990D02C-3998-406D-B471-6A38D1A3DE4FQ26746223-84AC0A12-68C0-4856-8E25-F6C52F65C1F4Q26748194-DFFADAB2-3353-4B11-8B8C-953A53EB06A6Q26748775-BDB4686C-42C3-4C00-B725-A7E40F7CF51BQ26770495-0C31C78E-7830-469C-8FDD-2D1B2F5A861CQ26774159-6ECBA92C-F390-47FA-94EF-EBD6F161B72CQ26781398-6B1FEA7D-EB52-46C7-AF93-0FAD05D4ABFFQ26786595-E47E9DAD-F411-4DD3-8191-09382A491A75Q26823555-BC01EBEB-4B95-4A6A-8D6D-B8C93CC52544Q26823660-7E9212C1-2A72-4BC5-ACC7-951979329A09Q26830075-CC333EA5-1705-4FAD-ABB2-D13B368467BFQ26858839-4C4A8261-A4BA-4EBF-82DC-F24724C6C2BDQ26864497-EA62921F-581F-408E-A96F-85FBEF9E129FQ27012444-C767A3DA-C796-4A5A-97E7-9E8004DAC669Q27014117-9A4FB20E-C89D-432C-B28E-2347C7409729Q27319519-7A635BBB-0BE6-4C74-B61B-2154554CF159Q27687567-A0597DC9-85CB-4BA8-B12A-E31C7986E9AFQ27692033-EC28FE34-C5D4-4538-AF49-A1779EA8397CQ28072798-FDFF93C8-C2C4-4C73-9C17-09BEFB8C1369Q28078667-B24EC54B-B337-49E0-846C-D8AF8D4ACB5DQ28480895-F422048A-A8D8-4827-85D3-EAC57727EE06Q28533194-5E4231ED-C22B-4EEC-A0C7-630A66939B65Q28541338-6057F5FA-F4F2-4B54-8BE7-97E69DD59E8EQ28543151-ED68B9DD-A343-4DC6-B122-21053B61CA4BQ28544732-5A3E4130-6981-45C5-BEEA-73B1C1D127B1Q28554490-60BFC1C2-63E9-468A-86AC-1754C942C301Q29615848-A3E8AF15-05D5-4EA5-B04C-AE860210B139Q30365752-978B1BC2-2C84-40D0-A95E-5988AC7D0D01Q30419311-5C5AF7AF-0DFE-416E-BBC0-3048E63FBCD5Q30427521-C0F89C7B-40B3-4306-9BC6-798DD0161A4DQ33418036-FE6C57BE-D6D1-4D10-826A-6E7115A41BF3Q33555526-701DD0D3-6092-40E3-9333-1FCF4B50118DQ33591632-48BE082B-3164-4095-813B-E009EC9296ACQ33597756-E27087BF-0F5D-423B-A705-272CFB4B566CQ33605145-02240004-CCF3-412F-B1E9-88AA766FF57BQ33636086-8C815CEB-2E26-4E00-9E33-4A06886569EEQ33641541-7D4E3580-9E41-401A-A9A9-4E27F9D9D4F6Q33648344-A87284B1-082F-4F1E-A1EB-7BAE936DAA3BQ33654609-7EE8F81C-FEF1-45B2-9E1E-5BD8859F6A7AQ33676440-0603F5FB-6240-402D-BE84-4E3A213B72C5
P2860
Environment-mediated drug resistance: a major contributor to minimal residual disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Environment-mediated drug resistance: a major contributor to minimal residual disease.
@en
Environment-mediated drug resistance: a major contributor to minimal residual disease.
@nl
type
label
Environment-mediated drug resistance: a major contributor to minimal residual disease.
@en
Environment-mediated drug resistance: a major contributor to minimal residual disease.
@nl
prefLabel
Environment-mediated drug resistance: a major contributor to minimal residual disease.
@en
Environment-mediated drug resistance: a major contributor to minimal residual disease.
@nl
P2093
P356
P1476
Environment-mediated drug resistance: a major contributor to minimal residual disease.
@en
P2093
Mark B Meads
Robert A Gatenby
William S Dalton
P2888
P304
P356
10.1038/NRC2714
P407
P577
2009-08-20T00:00:00Z